# overview
My research focuses on the discovery and development of novel therapies for colorectal cancer interception and investigating epigenetic pathways implicated in the early stages of the disease. As PI or co-Investigator on several NIH-funded grants, I laid the groundwork in identifying novel epigenetic mechanisms of dietary compounds that affect Wnt/?-catenin and DNA repair.

I also have extensive Pharma R&D expertise in developing novel anticancer drugs through close collaboration with R&D teams. As the Director of Antibody and Biopharmaceuticals Core (ABC), I support and advance the development of monoclonal antibodies.

# keywords[]
C-terminal Binding Protein (ctbp) Interacting Protein

# keywords[]
3205 Medical Biochemistry And Metabolomics

# keywords[]
5 Development Of Treatments And Therapeutic Interventions

# keywords[]
5 Development Of Treatments And Therapeutic Interventions

# keywords[]
5 Development Of Treatments And Therapeutic Interventions

# educationAndTraining[].organization.label
Birla Institute of Technology and Science, Pilani - Goa Campus - (Sancoale, India)

# publications[].label
Betulinic Acid and Its Derivatives as antiAngiogenic Agents.

# publications[].label
CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
S318 Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP

# publications[].label
Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas.

# publications[].label
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.

# publications[].label
Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception.

# publications[].label
Novel betullnic acid derivatives A-ring-condensed to a heterocyclic group

# publications[].label
Front cover: A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphanetreated colon cancer cells

# publications[].label
Anticancer activity of DRF7295: A peptide combination targeting multiple neuropeptide receptors in gastrointestinal cancers.

# publications[].label
Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling.

# publications[].label
A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells.

# publications[].label
Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling

# publications[].label
STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS

# publications[].label
Abstract A013: Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Targeting ACE2-BRD4 crosstalk in colorectal cancer and the deregulation of DNA repair and apoptosis.

# publications[].label
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.

# publications[].label
Metabolism as a key to histone deacetylase inhibition.

# publications[].label
Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine /2-bromo/20,29-dibromo betulinic acid derivatives.

# publications[].label
Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.

# publications[].label
Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.

# publications[].label
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis.

# publications[].label
Prevention by tolfenamic acid and characterization of the molecular targets in Pirc and FAP colorectal adenomas

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Differential effects of sulforaphane and related isothiocyanates on HDAC turnover and the DNA damage response in colon cancer cells

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS

# publications[].label
DRF7295: A novel peptide based signal transcluction modulator for the treatment of gastrointestinal carcinomas.

# publications[].label
Bombesin analogs containing alpha-amino-isobutyric acid with potent anticancer activity.

# publications[].label
Abstract 2614: CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells.

# publications[].label
Metabolomics of Acute vs. Chronic Spinach Intake in an Apc-Mutant Genetic Background: Linoleate and Butanoate Metabolites Targeting HDAC Activity and IFN- Signaling.

# publications[].label
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells.

# publications[].label
Histone Acyl Code in Precision Oncology: Mechanistic Insights from Dietary and Metabolic Factors

# publications[].label
Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.

# publications[].label
AZ of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer

# publications[].label
Discovery of adamantane based highly potent HDAC inhibitors.

# publications[].label
Development of a murine colonoscopic polypectomy model(withvideos).

# publications[].label
Abstract 5074: Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs.

# publications[].label
Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam.

# publications[].label
Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents.

# publications[].label
Novel betullnic acid derivatives A-ring-condensed to a heterocyclic group

# publications[].label
Betulinic acid and its derivatives as anti-angiogenic agents.

# publications[].label
Novel polypectomy system in a preclinical model of colon cancer

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Abstract 2106: Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells.

# publications[].label
Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

# publications[].label
HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.

# publications[].label
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.

# publications[].label
An epigenetic perspective on pharmacologic ascorbate in colon cancer

# publications[].label
Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP

# publications[].label
Dietary polyphenols as epigenetic 'reader' inhibitors

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon.

# publications[].label
Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).

# publications[].publisher
American Association for Cancer Research (AACR)

# publications[].label
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.

# researcherOn[].label
CCAR2 as a Target for Prevention of Colorectal Cancer

# researcherOn[].awardedBy.label
National Institutes of Health - (Bethesda, Maryland, United States)

# streetAddress
Texas A&M Health Science Center; Ibt - Cedp - Dashwood; 1201 TAMUS